


1/13



2/13




FIG. 2A

BEST AVAILABLE COPY

3/13




FIG.2B




FIG. 3A




FIG. 3B

5/13



FIG. 4A



FIG. 4B

Non-treated




FIG. 5A

Doxorubicin-treated tumors



FIG. 5C




FIG. 5B

7/13




FIG. 6

BEST AVAILABLE COPY

8/13

	<b>Control</b>	<b>Doxo (2x20 mg/ kg)</b>
<b>Tumor/ Kidney</b>	0.86	0.59
<b>Tumor/ Heart</b>	1.07	5.69
<b>Tumor/ Liver</b>	0.88	4.68
<b>Tumor/ Muscle</b>	1.61	8.66
<b>Tumor/ Fast tissue</b>	6.60	5.20
<b>Tumor/ Spleen</b>	2.42	3.86
<b>Tumor/ Lung</b>	1.07	2.52
<b>Tumor/ Blood</b>	1.43	3.50
<b>Tumor/Small intestine</b>	1.18	2.26
<b>Tumor</b>	0.07	1.28

FIG. 7



9/13




FIG. 8B




FIG. 8A

10/13




FIG. 9B





FIG. 9A


BEST AVAILABLE COPY

11/13



Ischemic kidney

FIG. 10A



Contralateral side kidney

FIG. 10B

BEST AVAILABLE COPY

12/13




FIG. 11

BEST AVAILABLE COPY

13/13




FIG. 12